INTERIM RESULTS FROM THE "AUTOR" STUDY, A EUROPEAN OBSERVATIONAL STUDY IN PEDIATRIC PATIENTS WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER- PATIENT CHARACTERISTICS AND 1-YEAR COSTS
Author(s)
Haynes V1, Quail D2, Lorenzo M2, Deix C3, Anand H21Eli Lilly and Company, Indianapolis, IN, USA, 2Eli Lilly and Company, Surrey, United Kingdom, 3Eli Lilly and Company, Vienna, Austria
Presentation Documents
OBJECTIVES: To characterize patient sample, treatment patterns, and provide 1-year costs of an ongoing observational study of pediatric Attention Deficit/Hyperactivity Disorder (ADHD) patients in Europe. METHODS: AUTOR is a European observational study investigating factors associated with ADHD severity changes across a 2-year follow-up period in patients aged 6-17 that are stable responders on their first pharmacotherapy. At baseline, patients must have taken their ADHD medication for 3-8 months and have a Clinical Global Impression Severity score ≤3 and Improvement score ≤2 compared to treatment initiation. Data were collected at months 0, 3, 6, 9, 12, 18, and 24. UK unit costs of health & social care (PSSRU 2011) were used for analysis. RESULTS: A total of 703 patients (Italy: 224 [32%], Romania: 196 [28%], Greece: 125 [18%], UK: 72 [10%], Slovenia: 42 [6%], Sweden: 21 [3%], Netherlands: 17 [2.4%], Denmark: 6 [1%]) were analyzed (98 out of 801 failed to meet entry criteria). Patient characteristics: mean (SD) age 10.7 (2.7) years, 99% Caucasian, 82% male, 76% combined ADHD subtype. Most prominent baseline comorbidities: oppositional defiant disorder (28%), anxiety (15%), dyslexia (20%), and other learning disorders (33%). Baseline medication: Stimulants=298 patients (51% methylphenidate, 49% long-acting methylphenidate), atomoxetine=393 patients, other pharmacotherapy=8 patients, drug combination=4 patients. Mean (SD) treatment duration before baseline: 4.9 (1.5) months. Mean (SD) total costs after 1 year: £7520 (7374.5), split into £3618 (4171.7) direct costs excluding treatment (48%), £1783 (2933.6) treatment costs (24%), and £2119 (4911.2) indirect costs (28%). After 1 year, 82 patients (12%) have discontinued and 621 patients (88%) are ongoing. CONCLUSIONS: The AUTOR sample differs from clinical trials in its higher prevalence of comorbid conditions. There is substantial 1-year mean cost associated with pediatric ADHD, even for stable responders on their pharmacotherapy. Notably, only one quarter of the cost of ADHD is due to medication.
Conference/Value in Health Info
2012-11, ISPOR Europe 2012, Berlin, Germany
Value in Health, Vol. 15, No. 7 (November 2012)
Code
PMH2
Topic
Clinical Outcomes
Topic Subcategory
Comparative Effectiveness or Efficacy
Disease
Mental Health